Related Experiment Video

Updated: Jun 16, 2026

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
10:03

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Published on: November 5, 2019

[Study on immunogenicity of group A and group C meningococcal conjugate vaccine with coupling group B meningococcal

Fu-Bao Ma1, Hong Tao, Hong-Jun Wang

  • 1Jiangsu Province Center for Disease Control and Prevention, Nanjing 210009, Jiangsu, China.

Zhongguo Yi Miao He Mian Yi
|January 21, 2010
PubMed

Insights

The Group A and C conjugate vaccine, coupled with Men B-OMP, demonstrated strong immunogenicity in children aged 3 months to 24 years. This new vaccine formulation proved safe and effective in stimulating immune responses against Meningococcal serogroups A, C, and B.

Area of Science:

  • Vaccinology
  • Immunology
  • Microbiology

Context:

  • Meningococcal disease remains a significant public health concern, particularly in infants and young children.
  • Current vaccines offer protection against specific serogroups, but broader coverage is desirable.
  • The development of conjugate vaccines incorporating outer membrane proteins enhances immunogenicity.

Purpose:

  • To assess the immunogenicity and safety of a novel conjugate vaccine combining Group A and C Meningococcal antigens with Group B Meningococcal Outer Membrane Protein (MenB-OMP).

Summary:

  • A double-blind randomized controlled trial involved 458 healthy children across various age groups (3 months to 24 years).
  • Participants received either the Group A and C conjugate vaccine with MenB-OMP or a control vaccine.
  • Immunogenicity was measured by Serum Bactericidal Assay (SBA) for Men A, C, and B antigens pre- and post-vaccination.
  • Results showed 97.65%-100% of children achieving a 4-fold or greater increase in SBA titers, with geometric mean titers ranging from 1:194 to 1:420, significantly higher than controls.

Impact:

  • The Group A and C conjugate vaccine with MenB-OMP is a safe and well-immunogenic vaccine candidate.
  • This vaccine has the potential to provide broader protection against multiple serogroups of Neisseria meningitidis.
  • Further research may support its inclusion in routine infant immunization schedules to reduce the burden of meningococcal disease.
Abstract

More Related Videos

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes13:53

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Published on: December 19, 2020

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria06:38

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

Related Concept Videos

Bacterial Meningitis II: Pathophysiology01:26

Bacterial Meningitis II: Pathophysiology

Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...
Bacterial Meningitis I: Introduction01:22

Bacterial Meningitis I: Introduction

Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...
Bacterial Meningitis01:24

Bacterial Meningitis

Bacterial meningitis is a severe infectious disease involving inflammation of the meninges, the protective membranes surrounding the brain and spinal cord. It occurs when pathogenic bacteria cross the blood–brain barrier and enter the cerebrospinal fluid. Common causative organisms include Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae type b, Listeria monocytogenes, and Escherichia coli K1. The exact route of entry varies by pathogen and host condition.Routes of Entry...
Conjugated Proteins02:50

Conjugated Proteins

Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...